Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0019829 (Hodgkin's disease)
 30,247 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The efficacy of treatment of 19 patients with malignant lymphoma presenting with mediastinal tumor was evaluated. They included 7 patients with Hodgkin's disease and 12 with non-Hodgkin's lymphoma (NHL). Numbers of patients with stage I, II, III and IV disease according to Ann-Arbor's classification were 6, 4, 3 and 6, respectively. Stage I patients were treated with CHOP therapy after radiotherapy (RT). Stage II and III patients were treated with RT after COP-BLAM chemotherapy. Stage IV patients were treated with COP-BLAM III regimen. Complete remission was achieved in 16 of 19 patients (84.2%), and partial remission in 2 (10.5%). All patients with Hodgkin's disease and 9 (75%) with NHL attained complete remission. All patients in stage I to III and 3 (50%) in stage IV achieved complete remission. Overall median survival was 66 months. The incidence of bone marrow involvement and bulky mass was significantly different between stage I.II and stage III.IV patients (p < 0.05). These results indicate that combination treatment with RT and chemotherapy with regimens including adriamycin was effective in patients with malignant lymphoma presenting with mediastinal tumor, especially in those without bone marrow infiltration and bulky mass.
 ...
PMID:[Bulky mediastinal malignant lymphoma]. 846 17

The advances in therapy for aggressive non-Hodgkin's lymphoma have improved the long-term outlook for patients with this disease. However, many questions still remain such as: which combination chemotherapy protocol is the best? Is it necessary to use a third generation regimen, or is CHOP (cyclophosphamide/doxorubicin/vincristine/prednisone) adequate? And finally is the extent of dose intensity that can be achieved with conventional therapy adequate in poor prognosis patients? Although several smaller comparative trials have been done, the four arm trial currently being performed by the South West Oncology Group (SWOG) will represent the largest trial designed to address this issue. One best protocol has not yet been identified as being superior to others for the therapy of patients with aggressive non-Hodgkin's lymphomas. However, certain subsets of patients may benefit from specific protocols. This information can hopefully be gleaned from subset analysis of the SWOG study in the future. At the present time, since one best therapy cannot be identified, physicians should chose a regimen that they are confident in and familiar with it's use. By utilizing a particular regimen, one can minimize the treatment-related mortality and optimize the patient's change for a good outcome. Subset analysis to identify particular groups that may benefit from higher dose intensity will be an important feature for future analysis.
 ...
PMID:What is the role of third generation regimens for initial therapy of non-Hodgkin's lymphomas? 848 72

We report the case of a young male patient, VIH (+), who was admitted in our hospital with severe epigastric pain. Endoscopical and histological diagnosis was primary gastric non-Hodgkin lymphoma without Helicobacter pylori. The patient was treated with chemotherapy by CHOP scheme (6 cycles), with high clinical improvement and endoscopical and histological regression of the lesion. We comment some features of this peculiar association.
 ...
PMID:[Primary gastric lymphoma in an HIV positive patient]. 851 40

A 49-year old man was admitted in November 1989, because of anemia, abnormal shadowing on chest X ray and hyperproteinemia. Biclonal gammopathy (IgG kappa + IgA kappa) was shown in serum, and Bence Jones protein in urine. The bone marrow examination showed an increased number of abnormal plasma cells (15.7%) and no evidence of lymphoma, A diagnosis of multiple myeloma (MM) was made. In April 1990, while the patient was treated with the modified M2 regiman, swelling of the right cervical lymph node was observed. Lymph node biopsy revealed that he had non-Hodgkin's Lymphoma (:NHL, diffuse, mixed, B cell type). He was retreated with the CHOP regimen for both disease, but died of respiratory failure in October. 1991. To establish the clonal origin of this case of concominant MM and B-cell NHL, the immunoglobulin gene rearrangements in his lymph node and bone marrow were analyzed. Southern blot analysis with the JH probe and Ck probe showed one common band and one different band in the two samples. Our data suggest that two B-cell malignancies may have arisen from a single B-cell progenitor.
 ...
PMID:[Molecular evidence for a single clonal origin in a patient with multiple myeloma and non-Hodgkin's lymphoma]. 853 28

An epidemiological study on 173 consecutive elderly malignant lymphoma patients age 65 years or over was performed and the clinical outcome of chemotherapy is reported. Of there, 131 patients (75.7%) had non-Hodgkin's lymphoma (NHL) and 21 patients had Hodgkin's disease (HD). As for clinical staging, 58.9% of patients were in stage 3 or 4. The initial sites were nodal in 61.8% of the patients the most common sites of involvement in superficial lymph nodes being cervical, inguinal and axillar. The most frequent site of extranodal involvement was the gastrointestinal tract. The cases were treated with CHOP/COPP, BACOP or COP-BLAM combination chemotherapy. The clinical efficacy of these modalities was similar, with complete remission rates being about 50%. However, the total response rate (CR+partial remission) by the COP-BLAM regimen were 88.1%. The median survival time of cases achieving CR, was longer than 47 months. The most frequent cause of death was infection, especially pneumonia and septicemia. Many elderly ML patients were found and diagnosed when the disease developed to an advanced stage. Therefore it is necessary to make efforts to find early ML patients by screening apparently healthy elderly people. Improvement of the complete remission rate should be obtained if vigorous and intensive chemotherapy is carried out with careful supportive therapy concerning the general condition and complications in patients.
 ...
PMID:[Clinical analysis of elderly patients with malignant lymphoma]. 853 1

Approximately 15-25% of malignant non-Hodgkin's lymphomas (NHLs) are primarily extranodal and only 2.7% of these are located in the genitourinary tract. Only a few particular cases of primary manifestation of NHL in the urethra have been described, most of them in female patients, whereas a secondary involvement occurs more frequently. In the present case a high-grade malignant NHL of the B-cell type was located in the urethra of a 29-year-old male patient. No other manifestations of NHL could be found. After surgical removal of the urethral neoplasm the patient was treated with combined chemotherapy (6 cycles of the CHOP scheme). Thereafter, reconstruction of the urethra by the island flap method of Duckett was carried out. Two years after diagnosis the patient is alive and in complete remission with good functional and cosmetic results of surgery and a normal sexual life.
 ...
PMID:Primary non-Hodgkin's lymphoma of the male urethra. A case report and review of the literature. 854 Jan 67

Between January 1988 and June 1992, 35 patients with primary anaplastic large cell lymphoma (ALCL)CD30+ were referred to one of the institutions participating in GISL (Gruppo Italiano per lo Studio dei Linformi). 16 patients were treated with ProMACE-CytaBOM, two with MACOP-B, one with CHOP and one with LSA2-L2. As of November 1990, all newly diagnosed patients were treated with MOPP/EBV/CAD hybrid. 27 (77%) cases of ALCL CD30+ and 8 (23%) cases of Hodgkin's-related (HR) lymphoma CD30+ were diagnosed. Extranodal disease was present in 22 cases (63%), and 8 patients (23%) had primary bone marrow involvement. Twenty-three complete remissions (CR) (66%), six partial remissions (PR) (17%) and six no remissions (NR) (17%) were achieved with induction therapy. Results achieved with ProMACE-CytaBOM and MOPP/EBV/CAD hybrid were comparable. The overall response rate (CR+PR) was 85% for patients with classic ALCL CD30+ and 87% for those with HR lymphoma CD30+. The 3 year estimated overall survival rate was 66% and the 3 year relapse free survival rate was 65% for the entire group. The only significant favourable prognostic factor was the achievement of CR with initial therapy. Our findings suggest that ALCL (CD30+/Ki-1+) has a clinical outcome similar to aggressive non-Hodgkin's lymphoma (NHL). The use of an anthracycline-containing regimen will provide a change of cure in approximately 65% of cases.
 ...
PMID:Anaplastic large cell lymphoma (CD30+/Ki-1+). Analysis of 35 cases followed at GISL centres. 854 Oct 96

To evaluate the clinical effects of the administration of recombinant human granulocyte-stimulating factor (rhG-CSF) post chemotherapy for patients with advanced-staged intermediate-grade or high-grade non-Hodgkin's malignant lymphoma (NHL), we conducted this multicenter study and compared the responses between both the regimens, CHOP as a first-generation chemotherapy and ProMACE/CytaBOM as a third-generation chemotherapy, when combined with the rhG-CSF administration. In this multicenter study, where forty patients were registered, patients in both the CHOP and ProMACE/CytaBOM groups were treated with the original regimen designs without the necessity of reducing drug dosages when combined with the administration of rhG-CSF. The administration of rhG-CSF post both of the cytotoxic therapies brought about much higher rates of complete remission in both the groups (CHOP, 75 percent; ProMACE/CytaBOM, 75 percent), as compared with those of the previous study without the rhG-CSF administration. Regarding response rates according to the International prognostic factor index, the CHOP group showed a lower rate of complete remission in patients with risk factors, compared with ProMACE/CytaBOM group. This result suggested that the administration of rhG-CSF may offer one important approach for improving the first-line therapy for aggressive NHL with high risk factors.
 ...
PMID:Administration of rhG-CSF increases complete remission rates after CHOP and ProMACE/CytaBOM for non-Hodgkin's lymphoma: a pilot study. Hokkaido Study Group of Malignant Lymphoma and rhG-CSF. 859 Aug 51

High grade non-Hodgkin's lymphomas comprise a group of heterogenous disorders of the lymphatic system with aggressive clinical behaviour. Extranodal disease manifestations are common, especially in immunocompromised patients [e.g. AIDS]. High-grade NHL are chemo- and radiosensitive. Anthracyclin-containing chemotherapy regimens have led to a significant improvement in prognosis. The CHOP-regime, consisting of doxorubicin, cyclophosphamide, oncovin and prednisolon, is the standard therapy that should be given outside of clinical trials. Age, bad performance status, elevated serum-LDH, presence of more than one extranodal manifestation and disease stage III or IV have been defined as clinically relevant prognostic factors. Current treatment strategies include dose intensification by interval shortening and dose escalation as well as high-dose chemotherapy, followed by autologous stem cell rescue. Patients receiving these experimental therapies should be treated within multicenter clinical trials.
 ...
PMID:[High-grade non-Hodgkin lymphoma: diagnosis and therapy]. 862 63

With CHOP, the standard protocol for the treatment of high-grade non-Hodgkin's lymphomas, about 40% of long term survival has been reported. A recent randomized comparison of CHOP vs. ProMACE-Cyta-BOM vs. m-BACOD vs. MACOP-B showed no advantage of these third generation protocols. The analysis of prognostic factors in several controlled trials and the results of the International Non-Hodgkin's Lymphoma Prognostic Factors Project identified stage, LDH, performance status and number of extranodal sites as the most important pretreatment factors. Already the pretreatment LDH-level (normal vs. enhanced) defines accurately cohorts of patients with low or high risk. Based on these results two cooperative trials were initiated: In trial A we are currently evaluating in a randomised fashion the concept of high dose chemotherapy (BEAM) with autologous stemcell rescue vs. a standard treatment for high risk patients < 60 years. In trial B low risk patients or high risk patients > 60 years are randomised to receive either CHOP or CHOEP at two or three weeks intervals.
 ...
PMID:[Integrative concept on the treatment of highly malignant non-Hodgkin lymphomas]. 864 97


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>